ASH 2018: Ibrutinib-Based Therapy Beats Standard of Care as First-Line in Young Patients With Chronic Lymphocytic Leukemia
Outcomes and toxicity profile were superior with ibrutinib plus rituximab relative to FCR chemoimmunotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.